Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFB | P00751 | 6/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23491516 | 0.83 | TRPA1 (0.44) | — | |
| SCHEMBL8523197 | 0.83 | CFB (0.36) | CFBDRD2DRD3 | |
| SCHEMBL29489966 | 0.83 | ATM (0.43) | CFBCHRNA7 | |
| SCHEMBL22473185 | 0.83 | CHRNB2 (0.53) | CFBCHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL12124887 | 0.83 | CHRNB2 (0.53) | CFBCHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL12128467 | 0.81 | CHRNB2 (0.51) | CFBCHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL12997532 | 0.81 | CYP19A1 (0.47) | DRD2DRD3 | |
| SCHEMBL6222954 | 0.78 | CFB (0.43) | CFB | |
| SCHEMBL23032155 | 0.78 | DRD2 (0.46) | DRD2 | |
| SCHEMBL20349553 | 0.78 | TRPA1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312248-A1 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors | NOVARTIS AG | 2008-12-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312248-A1 | Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors | FGFR1, FGF1, FGF2 | CFB 4483/4885DRD2 4822/4885DRD3 4804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.